Citigroup’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Citigroup’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,900	Closed	-$13K	–	7830
2017 Q3	$13K	Sell	5,900 -1,900	-24%	-$4.64K	﹤0.01%	6624
2017 Q2	$23K	Sell	7,800 -9,100	-54%	-$27.3K	﹤0.01%	6220
2017 Q1	$58K	Buy	16,900 +11,580	+218%	+$45.7K	﹤0.01%	5603
2016 Q4	$9K	Buy	5,320 +300	+6%	+$705	﹤0.01%	6797
2016 Q3	$17K	Buy	5,020 +2,080	+71%	+$7.86K	﹤0.01%	6304
2016 Q2	$13K	Buy	2,940 +2,030	+223%	+$9.18K	﹤0.01%	6437
2016 Q1	$5K	Sell	910 -1,000	-52%	-$13K	﹤0.01%	7049
2015 Q4	$33K	Buy	1,910 +780	+69%	+$18.6K	﹤0.01%	6225
2015 Q3	$24K	Buy	1,130 +900	+391%	+$30.8K	﹤0.01%	5925
2015 Q2	$11K	Buy	+230	New	+$13.8K	﹤0.01%	6447

Other funds holding OREX

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup's OREX Position: Q2 2018 in Review

Citigroup sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 39,243 shares — an estimated $8K sold.

Citigroup first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $4.02M in Q2 2013. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

Citigroup reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Citigroup sold 39,243 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $8K.
Citigroup first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
Citigroup's Orexigen Therapeutics, Inc. position peaked at $4.02M in Q2 2013.
4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Citigroup's 13F filing for Q2 2018, filed 10 Aug 2018.